BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana
January 12 2021 - 9:32AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that the Company installed
its PURE EP(tm) System and conducted first patient cases at
Memorial Hospital of South Bend, part of Beacon Health System, in
South Bend, Indiana.
PURE EP(tm) System evaluation is being conducted under the
leadership of Vinod Chauhan, M.D. and Deepak Gaba, M.D.
“We are very pleased to commence our clinical operations at
Memorial Hospital, an outstanding clinical site that is recognized
nationally for its commitment to high-quality care and innovation.
As we continue to learn more about the coronavirus and its
detrimental effects on cardiovascular health, we realize that
treating heart rhythm disorders has never been more important. We
recently initiated commercial sales of the PURE EP(tm) System. Our
team looks forward to helping as many physicians and patients as
possible as we expand our clinical footprint and provide the
infrastructure to achieve much more throughout 2021,” commented
Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies,
Inc.
To date, more than 450 patient cases have been conducted with
the PURE EP(tm) System by over 30 physicians across seven clinical
sites. BioSig is currently conducting patient cases under the
clinical trial titled “Novel Cardiac Signal Processing System for
Electrophysiology Procedures (PURE EP 2.0 Study)” at Texas Cardiac
Arrhythmia Research Foundation (TCARF) in Austin, Texas, Mayo
Clinic Florida Campus in Jacksonville, Florida, and Massachusets
General Hospital in Boston, MA.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024